Decoy Therapeutics (DCOY)
NASDAQ:DCOY
Want to see DCOY full AI Analyst Report?
DCOY Stock Chart & Stats
$5.81
-$0.06(-3.48%)
At close: 4:00 PM EST
$5.81
-$0.06(-3.48%)
Day’s Range― - ―
52-Week Range$4.32 - $416.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)356.88K
Market Cap
$3.88M
Enterprise Value-$3.94M
Total Cash (Recent Filing)$7.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding531,968
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.46
Enterprise Value/Ebitda0.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtZero reported debt provides durable financial flexibility for a pre‑commercial biotech. With no interest burden the company can prioritize R&D spending and partnership development without near‑term debt service constraints, easing financing timing while pursuing clinical milestones.
Diversified Non‑dilutive Funding & PartnershipsAccess to institutional and non‑dilutive support plus alliances with Google, NVIDIA and BARDA strengthens runway and validates the platform. These relationships provide technical resources, grant funding and program credibility that can sustain development without solely relying on equity dilution.
AI‑enabled Peptide Conjugate Therapeutics PlatformA focused platform targeting high unmet-need respiratory and GI oncology indications offers structural upside if preclinical programs progress. The combination of computational design with rapid synthesis could create a repeatable discovery engine and long‑term competitive differentiation.
Bears Say
Pre‑revenue With Ongoing LossesThe company remains pre‑commercial and cash‑consumptive, with sizable negative net income and operating cash flow. Persistent burn without product revenue means continued dependence on external financing, which can pressure strategy, timing of trials and increase dilution risk over the next several quarters.
Shrinking Stockholders' EquityA steady decline in equity signals capital erosion from cumulative losses and likely recurring financing. Reduced equity weakens the balance‑sheet buffer available for development setbacks and suggests future capital raises could be necessary, heightening dilution and limiting strategic optionality.
Ongoing Listing Sensitivity / MonitorAlthough Nasdaq compliance was restored via a reverse split, the Mandatory Panel Monitor through 2027 creates structural listing fragility. Any renewed bid‑price breach could trigger automatic delisting, increasing governance and financing risk and complicating long‑term investor and partner confidence.
Decoy Therapeutics News
DCOY FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was $4.32 and its highest was $416.05 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is $3.88M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Decoy Therapeutics has 531,968 shares outstanding.
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DCOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company is headquartered in Cambridge, MA.
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Scinai Immunotherapeutics
―
Oragenics
―
Onconetix
―
Ownership Overview
Options Prices
Currently, No data available
---